Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?
Open Access
- 12 March 2022
- journal article
- review article
- Published by Elsevier in The Journal of Nutrition
- Vol. 152 (6) , 1381-1403
Abstract
Human epidemiology suggests a protective effect of tomatoes or tomato phytochemicals, such as lycopene, on prostate cancer risk. However, human epidemiology alone cannot reveal causal relations. Laboratory animal models of prostate cancer provide opportunities to investigate hypotheses regarding dietary components in precisely controlled, experimental systems, contributing to our understanding of diet and cancer risk relations. We review the published studies evaluating the impact of tomatoes and/or lycopene in preclinical models of prostate carcinogenesis and tumorigenesis. The feeding of tomatoes or tomato components demonstrates anti–prostate cancer activity in both transplantable xenograft models of tumorigenesis and models of chemically- and genetically-driven carcinogenesis. Feeding pure lycopene shows anticancer activity in most studies, although outcomes vary by model system, suggesting that the impact of pure lycopene can depend on dose, duration, and specific carcinogenic processes represented in different models. Nonetheless, studies with the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of carcinogenesis typically demonstrate similar bioactivity to that of tomato feeding. In general, interventions that commence earlier in carcinogenesis and are sustained tend to be more efficacious. Accumulated data suggest that lycopene is one, but perhaps not the only, anticancer bioactive compound in tomatoes. Although it is clear that tomatoes and lycopene have anti–prostate cancer activity in rodent models, major knowledge gaps remain in understanding dose–response relations and molecular mechanisms of action. Published and future findings from rodent studies can provide guidance for translational scientists to design and execute informative human clinical trials of prostate cancer prevention or in support of therapy.Keywords
Funding Information
- National Cancer Institute (R01 CA125384)
- USDA
- Agricultural Research Service (3092-51000-056-03S, 3092-51000-059-NEW2S)
- ARS
- NIH
- NCI
This publication has 127 references indexed in Scilit:
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Mammalian Carotenoid-oxygenases: Key players for carotenoid function and homeostasisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Low-serum carotenoid concentrations and carotenoid interactions predict mortality in US adults: the Third National Health and Nutrition Examination SurveyNutrition Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The genomic complexity of primary human prostate cancerNature, 2011
- Chemoprevention of prostate cancer with lycopene in the TRAMP modelThe Prostate, 2010
- Identification and Quantification of Apo-lycopenals in Fruits, Vegetables, and Human PlasmaJournal of Agricultural and Food Chemistry, 2010
- Are the health attributes of lycopene related to its antioxidant function?Archives of Biochemistry and Biophysics, 2009
- The current state of preclinical prostate cancer animal modelsThe Prostate, 2008
- The Biochemical Characterization of Ferret Carotene-9′, 10′-Monooxygenase Catalyzing Cleavage of Carotenoids in Vitro and in VivoJournal of Biological Chemistry, 2006